The effect of vincristine on the biodistribution of technetium-99m DTPA, GHA, and DMSA in Balb/c female mice.
OBJECTIVE
Vincristine has been widely used in various chemotherapeutic protocols in oncology. The purpose of this study was to evaluate the effect of vincristine on the biodistribution of 99mTc-DMSA, 99mTc-GHA, and 99mTc-DTPA in Balb/c female mice.


METHODS
Vincristine (0.03 mg, 0.3 mL) was injected into female isogenic Balb/c mice (n = 15), in 3 doses over an interval of 96 h. The 99mTc-DMSA, 99mTc-GHA, or 99mTc-DTPA (7.4 MBq) was administered after the last dose of vincristine. After 0.5 h the animals were killed rapidly. The organs (pancreas, thyroid, brain, thymus, ovary, uterus, spleen, kidney, heart, stomach, lung, liver, bone, and lymph nodes) were isolated and the radioactivity in each organ was counted in a NaI(Tl) well counter. The percentage of radioactivity (%) in each was calculated and compared with the control group. Statistical analysis was performed by Wilcoxon test (P < 0.05).


RESULTS
The percentage of 99mTc-DMSA was increased in the lung, pancreas, heart, thyroid, brain, bone, and lymph nodes (inguinal and mesenteric). The percentage of 99mTc-GHA was decreased in the uterus, ovary, spleen, thymus, lymph nodes (inguinal and mesenteric), kidney, and heart. The percentage of 99mTc-DTPAwas increased in thymus, lymph nodes (inguinal and mesenteric), ovary, uterus, spleen, kidney, heart, stomach, lung, liver, and bone.


CONCLUSIONS
The results could be explained by the metabolization, toxic effect, therapeutic, or immunosupressive action of the studied chemotherapeutic drug.
Mattos
D M
DM
Instituto Nacional de Biologia Roberto Alcantara Gomes, Universidade do Estado do Rio de Janeiro, Brasil.
Gomes
M L
ML
Freitas
R S
RS
Boasquevisque
E M
EM
Cardoso
V N
VN
Paula
E F
EF
Bernardo-Filho
M
M
D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology*; D005260:Female; D051379:Mice; D008807:Mice, Inbred BALB C; D015609:Organotechnetium Compounds / Q000493:pharmacokinetics*; D019275:Radiopharmaceuticals / Q000493:pharmacokinetics*; D013400:Sugar Acids / Q000493:pharmacokinetics*; D019783:Technetium Tc 99m Dimercaptosuccinic Acid / Q000493:pharmacokinetics*; D016284:Technetium Tc 99m Pentetate / Q000493:pharmacokinetics*; D014018:Tissue Distribution; D014750:Vincristine / Q000494:pharmacology*
D000970:Antineoplastic Agents; D015609:Organotechnetium Compounds; D019275:Radiopharmaceuticals; D013400:Sugar Acids; D019783:Technetium Tc 99m Dimercaptosuccinic Acid; D014750:Vincristine; C100014:technetium Tc 99m gluceptate; D016284:Technetium Tc 99m Pentetate